Preparation of cannabinoid formulations containing: .DELTA.9-tetrahydrocannabinol (.DELTA.9-THC), .DELTA.8-tetrahydrocannabinol (.DELTA.8-THC), .DELTA.9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. The present invention demonstrates the viability of transdermal delivery with gels and patches for consistent and sustained cannabinoid dosing.

Nutrae, LLC

NUTRAE, LLC

Encapsulated cannabinoid formulations for transdermal delivery

Preparation of cannabinoid formulations containing: .DELTA.9-tetrahydrocannabinol (.DELTA.9-THC), .DELTA.8-tetrahydrocannabinol (.DELTA.8-THC), .DELTA.9-tetrahydrocannabinolic acid (THCa), cannabidiol (CBD), cannabidiolic acid (CBDa), cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN), either alone or in combinations henceforth known as Cannabis, have been created using an emulsification process to encapsulate cannabinoids. The aqueous-based method involves micellular encapsulation of cannabinoids, a method that has been used to increase the bioavailability of poorly permeable, lipophilic drugs. These preparations demonstrates the viability of sublingual, buccal, or oral delivery using an aqueous-based encapsulation method, including as a beverage or drink.

Encapsulated cannabinoid formulations for oral delivery

1'-substituted cannabinoid derivatives of delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, and delta-6a-10a-tetrahydrocannabinol that have affinity for the cannabinoid receptor type-1 (CB-1) and/or cannabinoid receptor type-2 (CB-2). Compounds having activity as either agonists or antagonists of the CB-1 and/or CB-2 receptors can be used for treating CB-1 or CB-2 mediated conditions.

delta 8 tetrahydrocannabinol/kanapė

Encapsulated cannabinoid formulations for transdermal delivery

Encapsulated cannabinoid formulations for oral delivery

Cannabinoid derivatives, methods of making, and use thereof

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu